Skip to main content

Dicerna, Ipsen Ink RNAi Drug-Discovery Deal

Premium

Dicerna Pharmaceuticals said this week that it has signed a deal with French biotechnology firm Ipsen to develop RNAi-based therapeutics in the areas of oncology and endocrinology.

Under the terms of the deal, the companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

Although the arrangement is focused on drug discovery, "Dicerna and Ipsen may collaborate further to move the programs discovered under this partnership into development and eventual commercialization," they noted.

Specific terms of the arrangement were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.